Decoding the landscape of bispecific antibodies in breast cancer: insights from a comprehensive trial analysis. [PDF]
Yang S, Chuan Z, Yang S, Nie J.
europepmc +1 more source
ABSTRACT Multiple myeloma (MM) is predominantly a disease of older adults, yet the randomized clinical trials (RCTs) that define standards of care are conducted largely in younger, fitter, and less comorbid populations. This creates a systematic mismatch between the populations generating evidence and those receiving treatment in routine practice ...
Enrica Antonia Martino +13 more
wiley +1 more source
Engineered bispecific antibodies achieve broad and potent protection against multiple ebolavirus species. [PDF]
Zhou J +15 more
europepmc +1 more source
ABSTRACT Objectives To determine the prevalence and prognostic significance of the SKY92 gene‐expression signature, evaluate minimal/measurable residual disease (MRD), and identify molecular drivers of high‐risk disease in transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in the Republic of Ireland.
Roisin M. McAvera +24 more
wiley +1 more source
Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture +3 more
wiley +1 more source
Infections after bispecific antibodies in B-cell lymphomas. [PDF]
Kim DH +9 more
europepmc +1 more source
FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita +2 more
wiley +1 more source
Efficacy of Bispecific Antibodies in Relapsed or Refractory Multiple Myeloma With Extramedullary Disease: A Systematic Review and Meta-Analysis. [PDF]
Burke OJ +3 more
europepmc +1 more source
Seventh Åland Island Meeting on von Willebrand Disease
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila +17 more
wiley +1 more source
Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma. [PDF]
Chohan KL +18 more
europepmc +1 more source

